Startup profile · funding coverage
Ollin Bio
Retina biotech developing OLN324, a VEGF/Ang2 bispecific for DME and wet AMD.
Stage
series b
Status
private
Coverage
full
Why Ollin Bio is interesting
Head-to-head beat Vabysmo in trials — a16z Bio+Health joined a $330M Series B (2026) co-led by ARCH and TCGX for global Phase III.
Key facts
- Series B (2026): $330M co-led by ARCH and TCGX; a16z Bio+Health participated (AllSci, press)
- Co-investors not in VCT directory: TCGX, Commodore Capital, RA Capital, CPP Investments
Investors in our directory
Funds linked from Ollin Bio's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences Healthtech
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Ollin Bio's financing or category context.
Last updated: 2026-07-24